Journal of
Medicinal Plant Research

Academic Journals

ABOUT JMPR

The Journal of Medicinal Plant Research is published weekly (one volume per year) by Academic Journals.

The Journal of Medicinal Plants Research (JMPR) is an open access journal that provides rapid publication (weekly) of articles in all areas of Medicinal Plants research, Ethnopharmacology, Fitoterapia, Phytomedicine etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in JMPR are peer reviewed. Electronic submission of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

Contact Us

Journal of Medicinal Plants Research

ARTICLES

Full Length Research Paper

Phytochemical composition, acute toxicity and phytohormonal activity of hydroalcoholic extract of *Pentadesma butyracea* (Clusiaceae Sabine (1824)) seeds

TINDANO Basile[1]*, BAYALA Balé[1], DOUKOURE Maya[1], BELEMTOUGRI G. Raymond[1], TAMBOURA H. Hamidou[2] and SAWADOGO Laya[1]

[1]Laboratory of Animal Physiology, Reproduction and endocrinology team, University Ouaga I Pr Joseph KI-ZERBO 03 BP 7021 Ouagadougou 03, Burkina Faso.
[2]Laboratoire de Biologie et Santé Animales, Institut de l'Environnement et de Recherches Agricoles (INERA). Centre National de la Recherche Scientifique et Technologique 01 BP 476 Ouagadougou 01, Burkina Faso.

Pentadesma butyracea **is a rainforest species of Clusiaceae family with multi-values for human healthcare according to previous ethnobotanical survey. In spite of this traditional use of *P. butyracea*, there is a lack of scientific knowledge of its biological activities. Therefore, the aim of this study was to identify the major phytochemical compounds of *P. butyracea* hydroalcoholic seeds extract and to assess phyto-hormonal activities. Phyto-chemical screening of dichloromethane and hydroalcoholic seeds extracts were achieved. Subsequently, acute toxicity study was performed on mice to assess extracts safety use. Phyto-hormonal activities of hydroalcoholic extract of seeds were evaluated by uterotrophic and Hershberger's bioassays. Phyto-chemical screening of seeds of *P. butyracea* showed the presence of flavonoids, tannins, phytosterols, polyphenols, leucoanthocyanes and fatty acids. Acute toxicity investigation showed no mortality of mice at the dose of 2000 mg/kg. Hydro-alcoholic extract of seeds significantly increased (p<0.05) the weight of uterus of immature female mice while prostate and seminal vesicles weight of immature male mice were significantly (p<0.05) reduced. In conclusion, the hydroalcoholic extract of seeds of *P. butyracea* is practically nontoxic and contains chemical groups which induced estrogenic and anti-androgenic activities. The seeds extract of *P. butyracea* have great potential which could be useful for management of menopausal symptoms disorders and hormone-sensitive diseases.**

Key words: *Pentadesma butyracea* extract*,* phyto-chemical, acute toxicity and phyto-hormonal activities*.*

INTRODUCTION

Natural products including medicinal plants have a great potential for human and animal well-being. Many pharmaceutical drugs are derived from medicinal plants (Rates, 2001) and until now, people from developing countries rely mostly on medicinal plants for their primary healthcare. Furthermore, medicinal plants and diets supplement can have a great benefit for treatment or prevention of chronic diseases such as cancers and cardiovascular diseases (Liu, 2003). Therefore, with the increase of chronic diseases cases in developing countries and especially in Burkina Faso, more interest should be given to the possible contribution of medicinal

plants for healthcare of low income people. Although this natural source of medication is cheap and efficient, there is a lack of scientific knowledge with regard to safety and active dose for several medicinal plants, which limits their rational use. *Pentadesma butyracea* is one of them.

P. butyracea is a dense forest species belonging to Clusiaceae family. It can be found in Western African countries such as Burkina Faso, Benin, Cameroon, Ghana, Côte d'Ivoire (Sinsin et al., 2003; Ouedraogo et al., 2013; Noudogbessi et al., 2013a). It is used by traditional healers to improve lactogenic activity of mammal, to manage breast pain and to treat pregnancy disorders such as abortion (Sinsin et al., 2003; Avocevou-Ayisso et al., 2011). Previous investigations (Batista et al., 2009; Tala et al., 2013; Noudogbessi et al., 2013b) showed that *P. butyracea* has anti-tumor and anti-plasmodial activities.

Nevertheless, few scientific investigations were performed to assess its biological activities on reproduction systems. Therefore, this study was conducted for two main objectives: to identify the major chemical compounds of *P. butyracea*, and to assess its acute toxicity and phyto-hormonal effects on mice reproduction tracts.

MATERIALS AND METHODS

Plant material

Seeds of *P. butyracea* were collected in June, 2013 from Banfora town located some 440 km from the capital Ouagadougou, in western part of Burkina Faso. These seeds were identified and authenticated by the Herbarium of University Ouaga I Pr. Joseph KI-ZERBO where a voucher specimen was deposited with a reference number (ID number: 16973, sample number: 6847). Seeds were air-dried in ventilated room, shielded from dust and sun.

Extraction and phytochemical screening

The dried seeds of *P. butyracea* were powdered with an electrical apparatus. One hundred gram of dried powdered was extracted in continuous extraction apparatus (soxhlet) until exhaustion successively with 500 ml of n-hexane, 500 ml of dichloromethane (DCM), 500 ml of acetate of ethyl and hydro-alcoholic solution 80% (v/v). The solvent of each extract was completely removed by evaporation (40 to 50°C) in a rotavapor. All the extracts were freeze-dried and stored at 4°C. The yield of the extraction was 39.64, 0.24, 3.8 and 12.63 % for n-hexane, DCM, acetate of ethyl and hydro-alcoholic solution, respectively. Various colorimetric tests were used on DCM and hydro-alcoholic seed extracts to identify the major groups of secondary metabolites according to Ciulei (1982). The following phytochemical compounds were checked, phytosterols and triterpens, flavonoids aglycones, anthracinosides aglycones, alkaloids, coumarins, cardenolides, fatty acids with high

molecules weight, flavonoids, leuco-anthocyans and tannins.

Chemicals

The 17β-estradiol (Purity 97%) was purchased from the Sigma Chemical Co. (St. Louis, MO, USA) and pantestone (testosterone undecanoate) was obtained from local pharmacy. The dimethylsulfoxid [DMSO 1% (v/v)] was used as dilution liquid for preparation of the various doses. All substances were shipped and stored in glass containers at room temperature. All solvents were of analytical grade.

Biological studies

Animal model and ethic consideration

Naval Medical and Research Institute (NMRI) mice of 5 to 7 weeks-old were obtained from the animal house of University Ouaga I Pr. Joseph KI-ZERBO. The room temperature was maintained at 22 ± 3°C with the 12 h light/12 h dark cycle and humidity at 50 ± 10%. The animals are fed with industrial pellets with 29% protein and have free access to drinking water. All the tests were performed according to the protocols already approved by the Department of Animal Physiology of University Ouaga I Pr. Joseph KI-ZERBO and met the international standards of animals' study (Zimmermann, 1983).

Acute toxicity

Acute toxicity was assessed as described previously (Organisation for Economic Co-operation and Development (OECD), 2001) with slight modification. Seven weeks-old mice of both sex weighting 24.53 ± 5.2 g were used. Twenty-four hours before test commenced, mice were fasted and 4 h before that time, drinking water was removed. Nine mice were randomly divided into 3 groups of 3 animals. One group received 1000 mg/kg body weight (BW); the 2nd; 2000 mg/kg BW and the 3rd one was treated with 0.24 ml of DMSO at 1% and constitutes the control group. All the mice were observed systematically for 1, 24, 48, 72 h after administration, with intoxication syndromes and mortality recorded.

Uterotrophic and Hershberger bioassay

Uterotrophic assay was achieved as described previously (OECD, 2007) with slight modification. Thirty immature female mice, 5 weeks-old and weighing 15 ± 2.11 g, were randomly divided into 5 groups of 6 mice each. The first group received 0.15 ml of DMSO at 1% and was considered as blank control. The second group received 10 µg/kg of 17β-estradiol and was considered as positive control. The three other groups received 50, 100 and 200 mg/kg of *P. butyracea*, respectively. All treatments were done intraperitoneally during 3 consecutive days.

For Hershberger assay, previous guideline for OECD (2009) was used with slight modification. Thirty-five immature male mice of 6 weeks old and weighed 20 ± 2.8 g were randomly divided into 5 groups of 7 mice. The first group was treated with 0.2 ml of DMSO at 1% and considered as blank control. The second group was

*Corresponding author. E-mail: tind3bas1@gmail.com.

Table 1. Phytochemical screening of DCM and hydroalcoholic extract of *P. butyracea* seeds.

Chemical groups	Extracts	
	DCM	Hydro-alcoholic
Phytosterols and triterpens	++	++
flavonoid aglycones	-	-
anthracinoside aglycones	-	-
Alkaloids	-	-
Coumarins	-	-
Cardenolides	+	-
Fatty acids with high molecule weight	++	++
Flavonoids	-	+
Leuco-anthocyans	-	++
Tannins	-	++
Saponosides	-	-
Alkaloid salt	-	-
Reducing compounds	-	++

++: abundant; +: average; -: no-detected.

treated with pantestone and was considered as positive control. The other three groups were treated, respectively with 50, 100 and 200 mg/kg of *P. butyracea*. All the treatment was done through intraperitoneal route administration for 10 consecutive days. Twenty-four hours after the last administration, mice were weighed and autopsied. Hormono-dependent sex glands were removed and separated from adherent tissues and weighed. Uteri, ovary, vagina and adrenal glands were removed and weighed for uterotrophic bioassay. For Hershberger bioassay, seminal vesicles, prostate, testicle, epididymis and elevator anis and bulbo-carvenous (LABC) were removed and weighed.

Statistical analysis

Data were presented as mean ± standard error of mean (SEM) and analyzed by using Graph Pad Prism version 5.03. One-way analysis of variance (ANOVA) followed by Dunnett's comparison test were used to assess differences between groups. A value of $p < 0.05$ was considered as statistically significant.

RESULTS

Phytochemical screening

Phyto-chemical screening of DCM and hydro-alcoholic extracts of *P. butyracea* seeds showed the presence of secondary metabolites such as tannins, phytosterols, triterpens, cardenolides and leuco-anthocyanes. Flavonoids were found only in hydro-alcoholic extract. Coumarins, alkaloids, anthracenosides and saponosides were not detected (Table 1).

Acute toxicity

After 72 h, no mortality was recorded at 1000 and 2000 mg/kg. Nevertheless, sleepiness behavior was recorded.

Uterotrophic bioassay

Animal body weight

Three consecutive days of treatment with hydro-alcoholic extract of *P. butyracea* seeds did not change significantly ($p > 0.05$) the animal body weight of groups treated with 50, 100 and 200 mg/kg BW when compared to control. Nevertheless, there were slight impairments of the body weight of animals given the extract (Figure 1).

Organ weight

The doses of 50, 100 and 200 mg/kg BW caused significant increase ($p < 0.05$) of the weight of uteri, ovaries and vagina in comparison to positive control (Figures 3 and 4). The weight of adrenal glands did not change significantly ($p > 0.05$) when compared to blank control (Figure 3).

Hershberger bioassay

Animal body weight

After ten consecutive days of treatment, the doses 50, 100 and 200 mg/kg BW of hydroalcoholic extract of *P. butyracea* seeds did not cause significant ($p>0.05$) change in immature mice body weight when compared to control groups (Figure 2). Nevertheless, the body weight of these animals was slightly impaired.

Organs weight

The doses 50, 100 and 200 mg/kg BW did not induce

Figure 1. Immature female mice (NMRI) body weight before and after 3 consecutive days of treatment with hydro-alcoholic extract of *P. butyracea* seeds (DMSO: dimethylsulfoxyd, E2: 17-β-estradiol, Pb: *Pentadesma butyracea*).

Figure 2. Immature male mice (NMRI) body weight before and after 10 consecutive days of treatment with hydro-alcoholic extract of *P. butyracea* seeds (DMSO: dimethylsulfoxyd, Pant.: Pantestone, Pb: *Pentadesma butyracea*).

Figure 3. Ovaries and adrenals weight of immature female mice (NMRI) treated with hydro-alcoholic extract of *P. butyracea* seeds after 3 consecutive days of treatment (DMSO, E2: 17-β-estradiol, Pb: *Pentadesma butyracea*, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$).

Figure 4. Uteri and vagina weight of immature female mice (NMRI) treated with hydro-alcoholic extract of *P. butyracea* seeds after 3 consecutive days of treatment (DMSO, E2: 17-β-estradiol, Pb: *Pentadesma butyracea*, *: $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$).

significant ($p>0.05$) change of epididymis and testicles weight in comparison to blank control (Figure 5). In comparison to positive control, the dose of 100 mg/kg BW of *P. butyracea* induced significant reduction ($p<0.05$)

Figure 5. Epididymides and testicles weight from immature mice (NMRI) treated with hydro-alcoholic extract of *P. butyracea* seeds for 3 consecutive days (DMSO, Pant.: Pantestone, Pb: *Pentadesma butyracea*, *: p < 0.05).

Figure 6. Prostate and adrenal glands weight from immature male mice (NMRI) treated with hydro-alcoholic extract of *P. butyracea* seeds for 10 consecutive days (DMSO, Pant.: Pantestone, Pb: *Pentadesma butyracea*, *: p < 0.05, **: p < 0.01, ***: p < 0.001).

of testicles weight (Figure 5). Prostate weight was reduced significantly (p<0.05) in comparison to control values whereas adrenals weight was significantly (p<0.05) increased with the dose of 50 and 100 mg/kg

BW (Figures 6 and 7). All the doses caused significant (p<0.05) decrease of seminal vesicles weight in comparison to blank control (Figure 7). LABC weight was reduced significantly (p<0.05) with dose of 100 mg/kg BW

**Figure 7.** LABC and seminal vesicles weight from immature male mice (NMRI) treated with hydro-alcoholic extract of *P. butyracea* seeds for 10 consecutive days (DMSO, LABC: levator anis and bulbocarvenous, Ves. Sem.: Seminal vesicles, Pant.: Pantestone, Pb: *Pentadesma butyracea*, *: $p < 0.05$, **$p < 0.01$, ***: $p < 0.001$).

when compared to control values (Figure 5).

DISCUSSION

Phytochemical screening showed that *P. butyracea* seeds contain secondary metabolites including phytosterols, triterpens, tannins, flavonoids and leuco-anthocyanes. Previously, phytochemical investigations on bark, roots and leaves showed the presence of similar phyto-chemical compounds in this plant (Tchobo et al., 2007, 2013; Noudogbessi et al., 2013a). However, some compounds such as coumarins and saponosides found by Noudogbessi et al. (2013a) were not detected in *P. butyracea* hydroalcoholic seeds extracts. This difference could be explained either by solvent used for the extraction or by the organ or growing locality soil of plant used for the extraction (Lachman et al., 2008; Kajdzanoska et al., 2011; Noudogbessi et al., 2013a).

Several investigations suggest that phytochemical compounds have health benefits including positive impact on cancer (prostate and breast), cardiovascular diseases prevention, and menopausal symptoms management (Bacciottini et al., 2007; Lui, 2003). Among phytochemicals from plants, flavonoids are the most mentioned as phytoestrogen and therefore, well-known as the compound which could be involved in several sex hormonal activities (Koffi et al., 2009; Aguiar and Barbosa, 2014). In our two extracts, flavonoids were found only in hydro-alcoholic extract, which has been selected for toxicological and *in vivo* assay.

P. butyracea seeds and butter are used in foodstuffs and traditional medicine (Sinsin et al., 2003; Avocevou-

Ayisso et al., 2011; Ouedraogo et al., 2013). For the first-time, acute toxicity of hydro-alcoholic extract of *P. butyracea* seeds on mice was investigated. No mortality was recorded and lethal dose (LD_{50}) of hydro-alcoholic seeds extract could be more than 2000 mg/kg according to OCDE 423 (2001). The extract can then be classified as practically non-toxic. Therefore its phytohormonal activities were investigated.

Reproductive target glands function is under the control of hypothalamo-pituitary-axis through steroidal hormones regulation. Therefore, reproductive organs, especially uterus are very sensitive to estrogen which is essentially produced by ovaries of mature mammals. Ovariectomized mice or immature mice have low level of estrogen. These mice need external source of estrogen for the growing or functionality of uterus and other accessory glands. This is the principle underlaying the use of uterotrophic bioassay to screen substances with estrogenic/anti-estrogenic activities (Padilla-Banks et al., 2001). Uterotrophic bioassay of hydro-alcoholic extract of *P. butyracea* seeds on immature female mice showed that the weight of estrogeno-dependent organs (uteri, vagina and ovaries) increased quite significantly. The hypothalomo-pituitary-gonadic axis of these animals was not yet functional and subsequently, the change in sex glands weight is probably due to the extract effect. These findings are consistent with Bayala et al. (2006) and Siangcham et al. (2010) who showed that estrogenic compounds induce an increase of sex glands weight, especially uterus. Indeed, estrogenic compounds cause this weight increase through mitotic activity and retention of substance in target cells, especially in uterus cell (Bayala et al., 2006; Lienou et al., 2012; Essien and

Effiong, 2014).

Hershberger bioassay showed that the extract caused a decrease of prostate, seminal vesicles and LABC weight. The extract could mediate anti-androgenic activity. It has been reported that the anti-androgenic compounds caused reduction of androgeno-dependent glands weight (Piyachaturawat et al., 1999; Bayala et al., 2011, 2012). Anti-androgenic activity can be exhibited by two essential ways (Rashed et al., 2014). Firstly, competitive action can be mediated between androgens and anti-androgens for binding androgen receptors. Secondly, anti-androgens could inhibit 5-α reductase activity, an enzyme which controls the conversion of testosterone to dihydro-testosterone, the more potent androgen acting substance on prostate. In both instances, androgeno-dependent sex glands functionality could be reduced and lead to a weight reduction.

P. butyracea is useful for management of hormone-dependent diseases and menopausal symptoms. Its use as foodstuffs could have benefic effects for prevention of hormone-dependent diseases. It has been reported that compounds which are able to interact with hormonal function can have great potential to relieve hormono-dependent related diseases (Saunier et al., 2011; Rashed et al., 2014). Many results claimed that plant extract with estrogenic activities can be used for management of menopausal symptoms (Geller and Studee, 2006; Xu et al., 2014). Furthermore, treatment with potential to decrease androgen hormone action is a good candidate for prostate disorders management (Grant and Ramasamy, 2012).

Conclusion

Hydroalcoholic extract of *P. butyracea* seeds is rich in secondary metabolites including phytosterols, triterpens, flavonoids, tannins, leuco-anthocyanes. Until 2000 mg/kg of BW, hydroalcoholic extract of *P. butyracea* seeds did not cause mortality of adult mice therefore, the extract is quite safe. Biological studies revealed that the extract has estrogenic and anti-androgenic activities on immature NMRI-spell out female and male mice, respectively. Therefore, *P. butyracea* is a good candidate for management of hormono-dependent diseases such as breast cancer, prostate cancer and menopausal symptoms. Nevertheless, subsequent investigations are needed.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGEMENTS

REFERENCES

Aguiar PM, Barbosa P (2014). Used of soy isoflavones on hormone replacement therapy during climacteric. Afr. J. Pharm. Pharmacol. 8(42):1071-1078.

Avocevou-Ayisso C, Avohou TH, Oumorou M, Dossou G, Sinsin B (2011). Ethnobotany of *Pentadesma butyracea* in Benin: A quantitative approach. Ethnobot. Res. Appl. 9:151-166.

Batista R, Junior A, De JS, Braga OA (2009). Plant derived antimalarial agent: New leads and efficient phytomedicines. Part II. Alkaloidal natural Products. Molecules 14:3037-3072.

Bayala B, Tamboura HH, Pellicer MTR, Zongo D, Traore A, Ouedraogo L, Malpaux B, Sawadogo L (2006). Effets œstrogéniques du macéré aqueux des feuilles de *Holarrhena floribunda* (G. Don) Dur & Sching chez la rate ovariectomisée. Biotechnol. Agron. Sci. Environ. 10(3):173-180.

Bayala B, Pellicer MTR, Bassole IHN, Belemtougri R, Tamboura HH, Malpaux B (2011). Effects of aqueous extracts of *Leptadenia hastata* (Pers.) Decne (Asclepiadiaceae) on male reproductive functions using castrated immature rats. Res. J. Med. Plant 5(2):180-188.

Bayala B, Téléfo PB, Savadogo A, Sawadogo L, Malpaux B (2012). Combined effects of Testosterone propionate and *Leptadenia hastata* Pers. (Decne) aqueous extracts on immature castrated male rats. J. Med. Plants Res. 6(15):2925-2931.

Bacciottini L, Falchettini A, Pampaloni B, Bartolini E, Carossino AM, Brandi ML (2007). Phytoestrogens: Food or drug? Clin. Cases Min. Bone Metab. 4(2):123-130.

Essien GE, Effiong GS (2014). Anti-progestationel, anti-ovulatory and anti-implantation potentials of methanolic extract of *Garcinia kola* seed in female rats. Int. J. Pharm. Pharmacol. 4(2):22-27.

Ciulei I (1982). Methodology for analysis of vegetable drug. Practical manual an industrial utilization of medicinal and aromatic plants, Bucharest, Ministry of chemical industry. 67p.

Geller ST, Studee L (2006). Contemporary alternatives to plants estrogens for menopause. Maturitas 55(1):3-13.

Grant P, Ramasamy S (2012). Update on plants derived anti-androgens. Int. J. Endocrinol. Metab. 10(2):497-502.

Kajdzanoska M, Petreska J, Stefova M (2011). Comparison of Different Extraction Solvent Mixtures for Characterization of Phenolic Compounds in Strawberries. J. Agric. Food Chem. 59:5272-5278.

Koffi N'G, Kadja B, Zihiri GN, Traore D, Ake-Assi L (2009). Screening phytochimique des quelques plantes ivoiriennes utilisées en pays Kobrou (Agboville, Côte d'Ivoire). Sci. Nat 6(1):1-15.

Lachman J, Hamouz K, Orsák M, Pivec V, Dvorák P, (2008). The influence of flesh colour and growing locality on polyphenolic content and antioxidant activity in potatoes. Sci. Horticult. 117:109-114.

Lienou LL, Téléfo BP, Bayala B, Yemele D, Tagne RS, Goka SC, Lemfact CM, Kouokeu C, Moundapi PF (2012). Effect of the aqueous extract of *Senecio biafrae* (Oliv. & Hiern) J. Moore on sexual maturation of immature female rat. BMC Complement. Altern. Med. 12-36.

Liu RH (2003). Health benefits of fruit and vegetables are from additive and synergistic combinations of phytochemicals. Am. J. Clin. Nutr. 78:517-520.

Noudogbessi JPA, Natta AK, Tchobo FP, Bogninou GS, Bothon ETD, Bossou AD, Figueredo G, Chalard P, Chalchat JC, Sahounhloue DCK (2013a). Phytochemical screening of *Pentadesma butyracea* Sabine (Clusiaceae) Acclimated in Benin by GC/MS. Anal. Chem. 2013:1-8.

Noudogbessi JP, Delort L, Chalard P, Billard H, Figuerodo G, Ruiz N, Chalchat JC, Sohounloue D, Chezet FC (2013b). Anti-proliferative activity of four aromatic plants of Benin. J. Nat. Prod. 6:123-131.

Organisation for Economic Co-operation and Development (OECD) (2001). Guideline for testing of chemicals, Acute oral toxicity-acute toxic class method. 423:1-14. Available at:

https://ntp.niehs.nih.gov/iccvam/suppdocs/feddocs/oecd/oecd_gl423.pdf

Organisation for Economic Co-operation and Development (OECD) (2007). Guideline for the testing of chemicals. Uterotrophic bioassay in rodents: a short-term screening test for estrogenic properties. 440: 21p. Available at: http://www.oecd-ilibrary.org/environment/test-no-440-uterotrophic-bioassay-in-rodents_9789264067417-en;jsessionid=bj0kajgdp5r26.x-oecd-live-03

Organisation for Economic Co-operation and Development (OECD) (2009). Guideline for testing of chemicals. Hershberger bioassay in rats: a short-term screening assay for (anti) androgenic properties, 440: 20p. Available at:http://www.oecd-ilibrary.org/environment/test-no-441-hershberger-bioassay-in-rats_9789264076334-en

Ouedraogo A, Lykke AM, Lankoandé B, Korbéogo G (2013). Potentials for promoting oil products identified from traditional knowledge of native trees of Burkina Faso. Ethnob. Res. Appl. 11:71-83.

Padilla-Banks E, Jefferson WN, Newblod RR (2001). The immature mouse is a suitable model for detection of oestrogenicity in Uterotropic Bioassay. Environ. Healths Persp. 109(8):821-826.

Piyachaturawat P, Timinkul A, Chuncharunee A, Suksamrarn A (1999). Effect of *Curcuma comosa* on fertility in rats. Pharm. Biol. 37(1):22-27.

Rashed MM, Shallan M, Mohamed DA, Fouda K, Hanna LM (2014). Biological evaluation of anti-androgenic effect of some plant foods. J. Food Nutr. Res. 2(9):645-651.

Rates SMK (2001). Plants as source of drugs. Toxicon 39(5):603-613. Available at: https://doi.org/10.1016/S0041-0101(00)00154-9

Saunier EF, Vivar OI, Rubenstein A, Zhao X, Olshansky M, Baggett S, Staub RE, Tagliaferri M, Cohen I, Speed TP, Baxter JD (2011). Estrogenic plant extracts reverse weight gain and fat accumulation without causing mammary gland or uterine proliferation. PloS one 6(12):e28333.

Siangcham T, Saenphet S, Saenphet K (2010). Estrogenic bioassay of *Pueraria mirifica* Airy Shaw & Suvatabandhu. J. Med. Plants Res. 4(9):741-744.

Sinsin B, Sinadouwirou AT (2003). Valorisation socio-économique et pérennité du *Pentadesma butyracea* Sabine en galeries forestières du Bénin. Cahiers Agric. 12(2):75-79.

Tala MF, Wabo HK, Zeng GZ, Ji CJ, Tane P, Tan NH (2013). A prenylated xanthone and antiproliferative compounds from leaves of *Pentadesma butyracea*. Phytochem. Lett. 6:326-330.

Tchobo FP, Natta AK, Barea B, Barouh N, Piombo G, Pina M,Villeneuse P, Soumanou MM, Sohounhloue DCK (2007). Characterization of *Pentadesma butyracea* Sabine butters of different production regions in Benin. J. Am. Oil Chem. Soc. 84:755-760.

Tchobo FP, Alain AG, Noudogbessi JP, Mickael L, Bruno B, Piombo G, Natta KA, Pierre V, Mansourou SM, Dominique SKC (2013). Evaluation of the chemical composition of *Pentadesma butyracea* butter defatted kernels. Int. J. Biosci. 3(1):101-108.

Xu Y, Ding J, Ma XP, Ma YH, Lui ZQ, Lin N (2014). Treatment with *Panax ginseng* antagonizes the estrogens receptor decline in ovariectomised mice. Int. J. Mol. Sci. 15:7827-7840.

Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16:109-110.

Full Length Research Paper

Anti-proliferative and cytotoxic effects of methanol extract of the leaves of *Momordica charantia* L. (Cucurbitaceae) on vascular smooth muscle cells (VSMC) and HT-29 cell lines

Ofuegbe S. O.[1], Oyagbemi A. A.[2], Omobowale T. O.[3], Fagbohun O. S.[4], Yakubu M. A.[5] and Adedapo A. A.[1]*

[1]Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
[2]Department of Veterinary Physiology and Biochemistry, Faculty of Veterinary Medicine, University of Ibadan, Oyo, Nigeria.
[3]Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Oyo, Nigeria.
[4]Department of Veterinary Microbiology, Faculty of Veterinary Medicine, University of Ibadan, Oyo, Nigeria.
[5]Department of Environmental and Interdisciplinary Sciences, College of Science, Engineering and Technology, Texas Southern University, Houston, TX, USA.

Momordica charantia has been used traditionally for the treatment of several ailments. Some natural plant products are known to exhibit cytotoxic or anti-proliferative effects on cancer cell lines, such plants offer a promising therapeutic approach as an anti-tumor agent. In this study, the anti-proliferative effects of graded concentrations of methanol leaf extract of _M. charantia_ (MEMC) at different point time was examined on vascular smooth muscle cells (VSMC), and human colorectal adenocarcinoma cell lines (HT-29) were investigated using the MTT proliferation assay. The result showed that after 24 and 48 h, the effect of MEMC on the VSMC alone and in the presence of the mitogens was more of proliferation. In the case of HT 29 cytotoxic study, the extract at all doses used caused a cytotoxic effect. The effect of the extract of _M. charantia_ was more pronounced and consistent at 72 h time point exhibiting cytotoxic actions against cancer cell lines, the extract showed no toxic action to normal cells. This suggests a possible use of the plant _M. charantia_ to identify compounds of possible interest in the treatment of cancer. While the extract possesses proliferative effects on the VSMCs, the reverse is the case, where it exhibited cell inhibitory effects on HT 29 cell lines indicating that the plant exhibit cytotoxic effects and could then serve as lead agents in the search for anticancer drugs from natural products.

Key words: Anticancer activity, *M. charantia*, HT 29, VSMC, VEGF, ET-1.

INTRODUCTION

Cancer refers to a series of conditions whereby abnormal cells begin to divide uncontrollably. Sometimes, cancer begins in a part of the body and then spreads to other parts, a process known as metastasis (Lewandowicz et al., 2000; Kleihues et al., 2002). Cancer is one of the major causes of death globally, it is responsible for

millions of death each year (Rachet et al., 2010.); the incidence of cancer was 90.5 million with about 8.8 million deaths recorded in 2015 (Global Burden of Disease (GBD), 2015). The most common form of cancer includes lung cancer, prostate cancer, colorectal cancer, breast cancer and stomach cancer.

Cancer therapy including chemotherapy, radiation therapy, immunotherapy and stem cell transplantation is associated with various side effects (Abdel-Wahab and Levine, 2010); this implies that researches should focus on discovering novel anticancer agents that are effective with minimal side-effects. There are plant-derived formulations with potential anticancer effect (Chopra and Doiphode, 2002; Aggarwal et al., 2004); these compounds with potential anticancer activity has provided important leads for the development of clinically relevant anticancer drugs (Aggarwal et al., 2003). Antioxidant-rich foods are known to be beneficial in the prevention of cancer, cardiovascular diseases, diabetes, and other oxidative-stress-related chronic diseases (Kähkönen et al., 1999; Johnson, 2004), likewise some cancer patients use agents derived from different plants or nutrients as complementary or alternative medicines, exclusively or concurrently with chemotherapy and/or radiotherapy (Riboli and Norat, 2003).

These products if well researched can represent a new source of compounds with potential antioxidant and antiapoptotic activity. Scientific studies have identified various pharmacologically active and antioxidant compounds that have limited toxicity to normal cells (Riboli and Norat, 2003; Manach et al., 2004; Leung et al., 2009). *Momordica charantia* is a creeper belonging to the family Cucurbitaceae, with all its parts, including the fruit having a bitter taste (Basch et al., 2003; Abhishek et al., 2004). *M. charantia* contains biologically active phytochemicals including triterpenes, proteins, and steroids (Potawale et al., 2008). The triterpenes present in *M. charantia* can inhibit the enzyme guanylate cyclase which is one of the enzymes required for the growth of leukemia and other cancer cells. Physiological actions of *M. charantia* include hypoglycemia, hypolipidemia, anti-viral, antibacterial, immunomodulatory and anticarcinogenic effect which is the main scope of this study (Jilka et al., 1983).

Growth inhibitory properties of *M. charantia* whole plant extract were first reported by West et al. (1971). Thereafter, many growth inhibitors have been isolated from *M. charantia* and its antiproliferative activity has been demonstrated in a variety of tumor cell lines (Akihisa et al., 2007). The fruit extract of *M. charantia* has been proven to be cytotoxic to leukemic lymphocytes thereby inducing antitumor activity *in vivo* (Lee-Huang et al., 1995). A number of preliminary *in vitro* and *in vivo* studies with the water-soluble extract of *M. charantia* and its various purified fractions have shown anti-cancer activity against human bladder carcinomas and breast cancers (Zhu, 1990; Anila and Vijayalakshmi, 2000).

Some proteins in bitter melon including MAP-30, MRK29, alpha-momocharin, beta-momocharin and momordicin have the ability to treat tumors and HIV (Yuan et al., 1999; El-Said and Al-Barak, 2011). Some proteins including alpha- and beta-momorcharins are known to inhibit HIV infections (Jjiratchariyakul. et al., 2001).

Clinical trials have found much evidence that *M. charantia* can improve immune cell function in patients with cancer (Cunnick et al., 1990; Yuan et al., 1999). In this work, the cytotoxic activity of methanol leaf extract of *M. charantia* on cancer cell lines as well as its effects on the normal cell *in vitro* was examined.

MATERIALS AND METHODS

Cells and reagents

Cell Titer 96 MTT (3-(4,5-dimethylthiazol-z-yl)-2,5-di-phenyl tetrazolium bromide microculture tetrazolium technique) (Promega Corporation Cat.# G3580), Human Colorectal Adenocarcinoma Cell lines (HT-29) (Sigma-Aldrich) and Vascular Smooth Muscle Cells (VSMC) (PromoCell, Germany), agarose (Bio-Rad), dimethylsulfoxide (DMSO), Dulbecco's modified eagle medium (DMEM) (GibThai, Thailand), foetal bovine serum (FBS 20%) (Stem Cell Technology, Canada), penicillin (100 U/mL) and streptomycin (100 µg/mL), tween-80, sodium bicarbonate, trypsin/EDTA, propidium iodide (PI), 1 mM L-glutamine, in a 5% CO_2 humidified incubator were all used.

Collection and preparation of plant sample (*Momordica charantia*)

Fresh leaves of *M. charantia* were collected from the campus of the University of Ibadan, Nigeria, in May/June 2013. The leaves were properly identified and authenticated at the Department of Botany, University of Ibadan and the Voucher Specimen (VSN: UIH-22563) was deposited at the herbarium of the Department of Botany, University of Ibadan.

Preparation of plant extract

The leaves were dried at room temperature (27 ± 2°C) and pulverized to a fine powder using an electric blender. The fine powder (400 g) was soaked and extracted in 90% methanol (1 L) using Soxhlet extractor for 3 days until complete extraction. The extracts were filtered through Whatman no 1 filter paper and the filterate was evaporated to dryness by a rotary evaporator (Yamato, Rotary Evaporator, model-RE 801, Japan) at 190 to 220 rpm and 40 to 50°C for 24 h under reduced pressure to give amorphous solid mass. The extract yield was 12%.

*Corresponding author. E-mail: adedapo2a@gmail.com.

Cell culture

HT-29 and VSMC were procured from National Center for Cell Sciences, Pune, India. Cells were cultured and maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 20% foetal calf serum (FCS, 20%), 1% glutamine and 1% penicillin-streptomycin (Gibco[R] by life Technologies) in an adherent tissue culture plate at 37°C in a humidified incubator containing 5% CO_2. 96 wells microtiter plate were seeded with 5×10^3 cells per well and incubated again in a humidified atmosphere with 5% CO_2 at 37°C in an incubator. When the seeded plates achieved confluency, the cells were treated with graded concentrations of methanol leaf extract of *M. charantia*

Evaluation of anticancer activity

Cell viability and cell proliferation assay

The antiproliferative effects of the methanol leaf extract of *M. charantia* L. (Cucurbitaceae) on vascular smooth muscle cells (VSMC) and human colorectal adenocarcinoma cell lines (HT-29) were studied using the cell titre 96 MTT proliferation assay where the viable cells were seeded at a density of 5×10^4 (100 µL/well). For VSMC, log concentrations of each extract at 200 and 800 µg/ml were added and incubated for 24 and 48 h time points. Incubation of the extracts in the presence of VEGF and ET-1 was also conducted at different time points. Different concentrations of the extract (200, 400 and 700 µg/ml) were added and incubated with the HT 29 cell lines for 24, 48 and 72 h time points.

MTT assay

Cell viability of HT 29 cells upon treatment with *M. charantia* fractions at different concentrations of 200 and 800 µg/ml, 200 µg/ml and VEGF, 800 µg/ml and VEGF, SPLC1, SPLC2 (VEGF 50 ng/ml) and SPLC3 (ET1 20 ng/ml) was assayed using MTT as described by Yedjou et al. (2006). Cells were cultured to confluence, trypsinized and plated in 96 well plates at an initial density of 10^5 cells/ml for cell proliferation assay. Twenty-four hours after plating, cells were treated with various concentrations (25 to 100 µg/ml) of the extract along with the control in the presence or absence of mitogens Ag II or LPS and cultured for 24 to 96 h to determine effects of treatment on cell growth. The blank sample contained medium only. MTT assay was performed at 24, 48 and 72 h. MTT assay works on the principle of the ability of the cell to reduce MTT to purple formazan in the mitochondria of living cells. The viable VSM cells were seeded at a density of 5×10^4 (100 µl/well) in 96-well plates and incubated in a humidified atmosphere of 5% CO_2 and 95% air at 37°C for 24 h to form a cell monolayer. MTT assay was performed over three days. On day one, the VSM cells were trypsinized after these have confluence and on the second day the cells were treated with GK, the final volume of the media was adjusted to 100 µl and the incubation continued. On day three, 20 µl of 5 mg/ml of MTT was added to each of the 96 wells but the well used as controls have no cell. After incubation for 72 h, the cells were centrifuged at 800 rpm for 5 min and the supernatant culture medium carefully aspirated. The cells were washed twice with PBS, with of 200 µl fresh medium containing added MTT (0.5 mg/ml). Further incubation was done for three and half hours at 37°C and the medium was carefully removed. The cells were centrifuged at 800 rpm for 5 min with the supernatant aspirated, followed by addition of 100 µl DMSO to each well and then 200 µl of MTT solvent was added. This was covered with tin foil and cells agitated on orbital shakers for 15 min to solubilize formazan crystals. Thereafter, the absorbance was read using microplate reader (Tecan, Switzerland) at 590 nm. The amount of colour produced is directly proportional to the number of viable cells. This procedure was repeated for VSMC which is the normal cell and observed at 24 and 48 h point time.

Effect of *M. charantia* fractions on cell proliferation rate was determined by viable cell count using a hemocytometer (Lee et al., 2003). HL60 cells (10^5 cells/ml) were placed in a 24-well plate and incubated with different fractions of *M. charantia* at a final concentration of 20 µg/ml for 5 days. Viable cell counts were determined on each day post-treatment using trypan blue dye exclusion assay using a light microscope (Leica, Germany).

Statistical analysis

The results were expressed as mean ± SD. Cell viability was calculated using MTT absorbance of the control and treated cells: % survival = (mean value treated sample/mean value of the untreated sample) * 100. The results were treated to a one-way analysis of variance (ANOVA) and subsequently to the Tukey multi comparison post-test using the statistical package Graph Pad prism version 5 (Graph Pad software, San Diego CA, USA). Values of $\alpha_{0.05}$ were considered as significant (Betty and Jonathan, 2003).

RESULTS

Effects of methanol leaf extract of *M. charantia* on VSMC

The result show that after 24 h, the effect of each extract of the plants on the VSMC alone and in the presence of the mitogens was more of differentiation and proliferation with the proliferation pronounced by the 800 µg/ml concentration at 24 h. At 48 h, the proliferation was more marked (for instance the 800 µg/ml of *M. charantia* in the presence of vascular endothelial growth factor (VEGF) caused 153.3% increase) except for the 200 µg/ml *M. charantia* in the presence of VEGF that caused 14.3% decrease in cell proliferation (Figures 1 and 2).

Effects of methanol leaf extract of *M. charantia* on HT 29 cell line

In this study, the extract at all doses used caused a cytotoxic effect. For instance, there was 77.1% decrease in cell proliferation for 400 µg/ml of *M. charantia* at 24 h. At 48 h, the cell inhibitory or cytotoxic effect was more pronounced at 200 µg/ml concentration of the extract. At 72 h point time, *M. charantia* at all concentrations (200, 400 and 700 µg/ml) exhibited considerable cytotoxic effects on HT 29 cell lines (Figures 3 to 5).

DISCUSSION

This study demonstrates for the first time the differentiation and regeneration ability of the *M. charantia* methanol leaf extract on VSMC which is the normal cell. The test concentrations did not exert a cytotoxic effect on VSMC even in the presence of mitogens. This result

Figure 1. Effect of methanol leaf extract of *M. charantia* on VSMC cell viability at 24 h time point. α: $\alpha_{0.05}$ when compared with SPLC 1; β, $\alpha_{0.05}$ when compared with SPLC 2 (VEGF 50 ng/ml); γ: $\alpha_{0.05}$ when compared with SPLC 3 (ET1 20 ng/ml).


Figure 2. Effect of the methanol leaf extract of *M. charantia* on VSMC cell viability at 48 h time point. α: $\alpha_{0.05}$ when compared with SPLC 1; β: $\alpha_{0.05}$ when compared with SPLC 2 (VEGF 50 ng/ml); γ: $\alpha_{0.05}$ when compared with SPLC 3 (ET1 20 ng/ml).

Figure 3. Effect of methanol leaf extract *M. charantia* on HT 29 cell lines at 24 h. **α**: Significant values when compared with control at **α$_{0.05}$**.


Figure 4. Effect of methanol leaf extract of *M. charantia* on HT 29 cell lines at 48 h. α: Significant values when compared with control at α$_{0.05}$.

Figure 5. Effect of methanol leaf extract *M. charantia* on HT 29 cell lines at 72 h. α: Significant values when compared with control at $α_{0.05}$.

supports our claims in a previous study that the methanol leaf extract of *M. charantia* caused regeneration and proliferation of pancreatic beta cells.

In the case of HT 29 cytotoxic study, the extracts at all doses used caused a cytotoxic effect. There was 77.1% decrease in cell proliferation for 400 µg/ml of *M. charantia* at 24 h. The effect of the extract of *M. charantia* was more pronounced and consistent at 72 h time point. Chia-Jung et al. (2012) reported that *M. charantia* extract causes mitochondria- related cell death in human cancer cells through Caspase- and mitochondria-dependent pathways. Thus methanol leaf extract of *M. charantia* exhibited cytotoxicity on HT 29 cells, due to its ability to induce cell death in cancer.

The result from this study showed that while the extract had proliferative effects on the VSMCs, the reverse is the case, where it exhibited cell inhibitory effects on HT 29 cell lines indicating its cytotoxic effects. This study is consistent with the reports of Jutamas et al. (2015) which explained that plumericin isolated from *M. charantia* vine exerts antiproliferative effects against leukemic, breast and liver cancer cell lines.

Terpenes, a phytochemical present in *M. charantia* (Chang et al., 2008) have been reported to have anti-proliferative effect (Akhisa et al., 2007). This suggests that terpenes contributed to the anti-proliferative effect of *M. charantia* observed on the cancer cell lines.

The findings of this study negate the report of Soundararajan et al. (2012) which explained that *M. charantia* seed fractions did not exhibit any antiproliferative activity. However, Soundararajan et al. (2012) reported that the differentiation-inducing fraction in M. charantia was non-proteinaceous in nature, showing that the differentiation-inducing factor of M. charantia is different from its antitumor factors. Thus, the present study for the first time describes the differentiation inducing action of the methanol leaf extract of *M. charantia* which can be further studied as an inducer of differentiation and regeneration of normal cell, either alone or combined with the suboptimal concentrations of other known inducers of differentiation.

As a result of this study, it can be recommended that the methanol leaf extract of *M. charantia* can be combined with the known anticancer agent in order to act synergistically for a more effective treatment of cancer. The rationale being that the commercially available anti-cancer drugs in high concentrations not only kill cancer cells but also healthy normal cells in the body (Nagasawa et al., 2002). Therefore, a low to moderate dose of the anticancer drug (either temozolomide or vinblastine) can

be combined with a high dose of the crude methanol extract of *M. charantia* to produce a maximal anti-cancer effect, without killing healthy cells.

Conclusion

This study has demonstrated that the crude methanol leaf extract of *M. charantia* can cause a significant decrease in cancer cell viability (an increase in cell death) without being harmful or injurious to healthy cell lines like smooth muscle cell line. These effects were both time and dose-dependent with maximal effect occurring after 72 h at a dose of 200 μg for the methanol leaf extract of *M. charantia*. Therefore, *M. charantia* is cytotoxic to cancer cell lines (that is, it has anticancer property since it induces cell death) while it has no cytotoxic but caused regeneration of normal cells. Thus, *M. charantia* represents a promising candidate that could be developed for cancer prevention and treatment in the future.

CONFLICT OF INTERESTS

The authors have not declared any conflict of interests.

ACKNOWLEDGEMENT

REFERENCES

Abdel-Wahab O, Levine RL (2010). Recent advances in the treatment of acute myeloid leukemia. F1000 Med. Rep. 2(1):55.

Abhishek T, Sudhir K, Mangala D (2004). Phytochemical determination and extraction of *Momordica charantia* fruit and its hypoglycaemic potentiation of oral hypoglycaemic drugs in diabetes mellitus (NIDDM). Indian J. Pharm. 48:241-244.

Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. A. 24(5):2783-2840.

Aggarwal BB, Kumar A, Bharti AC (2003). Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. A 23(1):363-398.

Akhisa T, Higo N, Tokuda H, Ukiya M, Akazawa H, Tochigi H, Kimura Y, Suzuki T, Nishino H (2007). Cucurbitane-type triterpenoids from the fruits of *Momordica charantia* and their cancer chemopreventive effects. J. Nat. Prod. 70(8):1233-1239.

Anila L, Vijayalakshmi NR (2000). Beneficial effects of flavonoids from *Sesamum indicum*, *Emblica officinalis* and *Momordica charantia*. Phytother. Res. 14:592-595.

Basch E, Gabardi S, Ulbricht C (2003). Bitter melon (*Momordica charantia*): A review of efficacy and safety. Am. J. Health Syst. Pharm. 65:356-359.

Betty RK, Jonathan AC (2003). Essential medical statistics. Kirkwood

and Jonathan AC Sterne: Blackwell Science Ltd. pp. 414-425.

Chang CI, Chen CR, Liao YW, Cheng HL, Chen YC, Chou CH (2008). Cucurbitane-type triterpenoids from the stems of *Momordica charantia*. Nature 71:1327-1330.

Chia-Jung L, Shih-Fang T, Chun-Hao T, Hsin-Yi T, Jong-Ho C, Hsue-Yin H (2012). *Momordica charantia* extract induces apoptosis in human cancer cells through caspase- and mitochondria-dependent pathways. Evid. Based Complement Altern. Med. 2012:261971.

Chopra A, Doiphode VV (2002). Ayurvedic medicine: core concept, therapeutic principles, and current relevance. Med. Clin. 86(1):75-89.

Cunnick JE, Sakamoto K, Chapes SK, Fortner GW, Takemoto DJ (1990). Induction of tumor cytotoxic immune cells using a protein from the bitter melon (*Momordica charantia*). Cell. Immunol. 126:278-289.

El-Said SM, Al-Barak AS (2011). Extraction of insulin like compounds from bitter melon plants. Am. J. Drug Dis. Dev. 1(1):1-7.

Global Burden of Disease (GBD) (2015). Mortality and Causes of Death, Collaborators. (8 October 2016). Global, regional and national life expectancy, all-cause mortality and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study. Lancet 388(10053):1459-1544.

Jilka CB, Strifler WG, Fortner FE, Takemoto JD (1983). *In vivo* antitumor activity of the bitter melon (*Momordica charantia*). Cancer Res. 43:5151-5155.

Jjiratchariyakul WC, Wiwat M, Vongsakul A, Somanabandhu WL, fujii NS, Ebizuka Y (2001). HIV inhibitor from Thai bitter gourd. Planta Med. 67: 350-353.

Johnson IT (2004). New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutat. Res. 551(1-2):9-28.

Jutamas S, Sumonthip K, Nuttawan Y, Tanawan K, Weena J (2015). Antibacterial and antiproliferative activities of Plumericin, an iridoid isolated from *Momordica charantia* vine. Evid. Based Complement. Altern. Med. 2015:10.

Kähkönen MP, Hopia AI, Vuorela HJ (1999). Antioxidant activity of plant extracts containing phenolic compounds. J. Agric. Food Chem. 47(10):3954-3962.

Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002). The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61(3):215-225.

Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, Ye JM, Lee CH, Oh WK, Kim CT (2003). Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55:2256-2264.

Lee-Huang S, Huang PL, Chen HC (1995). Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 161(2):151-156.

Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S (2009). Anti-diabetic and hypoglycaemic effects of *Momordica charantia* (bitter melon): A mini review. Br. J. Nutr. 102(12):1703-1708.

Lewandowicz GM, Harding B, Harkness W, Hayward R, Thomas DG, Darling JL (2000). Chemosensitivity in childhood brain tumours *in vitro*: evidence of differential sensitivity to lomustine (CCNU) and vincristine. Cancer 36:1955-1964.

Manach C, Scalbert A, Morand C, Remesy C, Jimenez L (2004). Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 79(5):727-747.

Nagasawa H, Watanabe K, Inatomi H (2002). Effects of bitter melon (*Momordica charantia*) or ginger rhizome (*Zingiber offifinale* Rosc.) on spontaneous mammary tumorigenesis in SHN mice. J. Clin. Med. 30(2):195-205.

Potawale SS, Bhandari A, Jadhav H, Dhalawat Y, Vetal P, Deshpande RD (2008). A Review on Phytochemical and Pharmacological Properties of *Momordica Charantia* Linn. Pharmacoglycine 2:319-335.

Rachet B, Ellis L, Maringe C, Chu T, Nur U, Quaresma M, Shah A, Walters S, Woods L, Forman D, Coleman MP (2010). Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Br. J. Cancer 103(4):446-453.

Riboli E, Norat T (2003). Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am. J. Clin. Nutr. 78(3):559S-569S.

Soundararajan R, Prabha P, Rai U, and Dixit A (2012). Antileukemic

potential of *Momordica charantia* seed extracts on human myeloid leukemic HL60 cells. Evidence-Based Complement. Altern. Med. 2012:10.

West ME, Sidrak GH, Street SP (1971). The anti-growth properties of extracts from *Momordica charantia* L. West Indian Med. J. 20(1):25-34.

Yedjou CG, Moore P, Tchounwou (2006). Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment. Int. J. Environ. Res. Pub. Health 3(2):136-140.

Yuan YR, He YN, Xiong JP, Xia ZX (1999). Three-dimensional structure of beta-momorcharin at 2.55 a resolution. Acta Crystallogr. D Biol. Crystallogr. 55(Pt 6):1144-1151.

Zhu ZJ, Zhong ZC, Luo ZY, Xiao ZY (1990). Studies on the active constituents of *Momordica charantia* L. Yaoxue Xuebao 25:898-903.

Journal of
Medicinal Plant Research

Related Journals Published by Academic Journals

- *African Journal of Pharmacy and Pharmacology*
- *Journal of Dentistry and Oral Hygiene*
- *International Journal of Nursing and Midwifery*
- *Journal of Parasitology and Vector Biology*
- *Journal of Pharmacognosy and Phytotherapy*
- *Journal of Toxicology and Environmental Health Sciences*